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Abstract 
Discovered in 2003 at the Royal Veterinary College, London, canine respiratory 
coronavirus (CRCoV) is a betacoronavirus of dogs and major cause of canine 
infectious respiratory disease complex (CIRDC). Generally causing mild clinical signs 
of persistent cough and nasal discharge, the virus is highly infectious and is most 
prevalent in rehoming shelters worldwide where dogs are often closely housed and 
infections endemic. As the world grapples with the current COVID-19 pandemic the 
scientific community is searching for a greater understanding of a novel virus infecting 
humans. Similar to other betacoronaviruses, SARS-CoV-2 appears to have crossed 
the species barrier, most likely from bats, clearly reinforcing the One Health concept. 
Veterinary pathologists are familiar with coronavirus infections in animals and now 
more than ever this knowledge and understanding, based on many years of veterinary 
research, could provide valuable answers for our medical colleagues. Here I review 
the early research on CRCoV where seroprevalence, early immune response and 
pathogenesis are some of the same key questions being asked by scientists globally 
during the current SARS-CoV-2 pandemic.  
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In 2004 I began my PhD studies on a novel respiratory coronavirus of dogs that had 
been discovered the previous year by a colleague and now board-certified veterinary 
pathologist, Dr Kerstin Erles, at the Royal Veterinary College, London.5 The group I 
joined, as an eager and recently qualified veterinarian, had been working with a large 
rehoming shelter in London to investigate possible causes of respiratory disease in 
their dogs, despite the use of vaccines.3  My role was to investigate a) the prevalence 
of the virus in the UK and wider dog population, b) determine the effects of the virus 
on the upper respiratory tract and c) understand the early innate immune response to 
the virus in vitro.  
Just one year earlier, between November 2002 and June 2003, a novel human 
respiratory coronavirus (now known as SARS-CoV-1) had emerged in Guangdong 
province in southern China and spread to neighboring Hong Kong and latterly to other 
parts of the Asia-Pacific region.7 Initial reports of a new atypical pneumonia were rather 
patchy and news somewhat suppressed, but what subsequently emerged was a 
sudden, albeit rather short-lived, global interest in betacoronaviruses. A further 
relatively modest flurry of research interest surrounded the emergence of another 
betacoronavirus in Saudi Arabia in 2012 (now known as MERS-CoV).19 Although 
associated with more significant morbidity, it’s limited geographic reach perhaps, not 
sparking the required level of concerted international research effort into these viruses.  
The virus I worked with, canine respiratory coronavirus (CRCoV), is genetically closely 
related to the well-established betacoronavirus of humans HCoV-OC43 (one cause of 
the common cold) and bovine coronavirus (BCoV).5 Indeed, it is likely that all three 
viruses have a common ancestor. Many betacoronaviruses, including SARS-CoV-1 
and MERS-CoV, are thought to have emerged from bats. Indeed, various species of 
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bats are natural reservoirs for these viruses, which crucially possess both cross-
species and zoonotic transmission ability.2  
And so, in spring 2020 with the global COVID-19 pandemic well established, we find 
ourselves ‘locked down’ or ‘sheltering in place’ but asking the very same questions of 
another novel betacoronavirus now infecting the respiratory tract of humans, as I did 
with dogs in 2004. Looking back, almost sixteen years since commencing my PhD, I 
can’t help but think……this all sounds rather familiar… ‘I better go dust off that thesis!’. 
Here I summarize our early investigations into CRCoV, now known to be a common 
and widespread cause of canine infectious respiratory disease complex (CIRDC), 
which has many parallels with the current research efforts underway globally with 
SARS-CoV-2.14 
Prevalence of the virus 
From our initial work investigating the possible etiological agents of CIRDC in a large 
UK rehoming center we demonstrated a strong association between exposure to 
CRCoV and the development of respiratory disease in dogs entering the shelter. We 
knew, based on reverse transcription polymerase chain reaction (RT-PCR) testing, 
that the virus was present and circulating within this one large shelter, but we did not 
know if it was present more widely within the UK canine population, or globally. 
Given the very close genetic relationship to BCoV, we developed an ELISA based on 
a commercially available BCoV antigen which we then used to test sera from UK dogs 
through a collaboration with a large UK diagnostic laboratory. Using left-over sera 
which would otherwise have been discarded we were able to show that 36% of UK 
client-owned dogs had antibodies to a betacoronavirus.12  
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Until this point we had not been successful in culturing the virus in vitro, but a 
breakthrough came with the use of human rectal tumor cells (HRT-18G, derived from 
a colorectal adenocarcinoma) in which the virus grew to a high titre and without 
requirement for adaptation (Fig. 1-2).4 This latter finding was particularly interesting in 
light of the current pandemic in which SARS-CoV-2 has been demonstrated to infect 
secretory epithelia of the human gastrointestinal tract, possibly suggesting a dual 
tissue tropism of the supposed ‘respiratory’ betacoronaviruses.18  
With viral culture optimized, we were able to refine the ELISA technique using an 
antigen prepared as a whole-cell lysate of CRCoV-infected cells and confirmed the 
previously estimated seroprevalence in the UK. Through a collaboration with 
University of Bari in Italy and Cornell University in USA, we then showed the presence 
of antibodies to the virus in dogs from Italy (23.3%) and USA (54.7%).12,15 
Subsequently, other groups have demonstrated a global distribution based on 
presence of antibodies to the virus. 
Limitations of serological methods are clear and highly relevant to the current research 
underway with COVID-19. Seroprevalence gives an indication of previous viral 
infection, not active infection, and importantly we are still unclear how long antibodies 
to CRCoV remain detectable following infection. This is a particular problem for animal 
shelters – the very places where, largely due to the efficient spread between closely 
housed dogs, the virus is most prevalent. Since the turnover of dogs in these shelters 
is generally high, repeated exposure to an endemic virus also likely acts to repeatedly 
‘boost’ the immune response, and the ability to re-test an individual dog is limited as 
many have left the shelter within a 3-4-week period. Specificity of the CRCoV ELISA 
was assessed and antibodies to the canine (enteric) coronavirus, an alphacoronavirus 
and the only known other coronavirus of dogs, were not cross-reactive.15 
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Antibodies to CRCoV were detected in 99% of dogs within three weeks of entry to the 
large UK shelter, versus only 30% on entry, indicating a highly contagious virus.3 
Spread of the infection does not require direct contact between animals, and inhalation 
of air-borne respiratory secretions is the most likely route of transmission. Supporting 
the infectivity of the virus, CRCoV infection typically occurs in the first week after arrival 
to a re-homing shelter, while infections with canine parainfluenza virus and canine 
herpesvirus occur later, in weeks two and three respectively.3 Indeed, CRCoV has in 
most countries emerged as the predominant cause of CIRDC, and no vaccine is as 
yet commercially available. 
By way of an aside, a recent study from Italy demonstrated 100% identity between 
one of the main antigenic epitopes (and >80% for two other epitopes) of the CRCoV 
spike protein and SARS-CoV-2, highlighting how studying the immune response to 
this natural infection in the dog could offer useful insights on COVID-19.16 
 
Clinical disease and pathogenesis  
Our group showed that dogs possessing neutralizing antibodies to CRCoV on the day 
of entry to the shelter were at much less risk of developing CIRDC.5 Collective findings 
from outbreaks and clinical cases indicated that CRCoV is associated with generally 
mild respiratory disease, with typical clinical signs including a dry cough and nasal 
discharge, but what we needed was a greater understanding of the infection at the 
tissue and cellular level. 
Using canine tracheal explant cultures, we created an air-interface (‘organotypic’) 
model to recapitulate as closely as possible the environment of the canine upper 
respiratory tract. These 1 x 1cm explants were used to assess the functional effects 
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of the virus on mucociliary clearance and identify which cells are infected using 
immunohistochemistry. This technique was both technically challenging and time-
consuming but provided data to show that there was a clear and consistent association 
between CRCoV infection and inflammation in the nares and trachea, accompanied 
by significant injury such as shortening and clumping or loss of tracheal cilia (Figs. 3-
4).10 CRCoV significantly reduced mucociliary clearance and that both ciliated and 
goblet cells were infected by the virus (Fig. 5).13 Later studies using experimentally 
infected dogs revealed identical immunohistochemical labelling of bronchiolar 
epithelium in the lower airways (Fig. 6). Perivascular and peribronchiolar lymphoid 
aggregates were observed in the lungs, but changes were less significant and more 
variable than those within the upper airways. Histopathological changes were 
apparent at the earliest euthanasia time point at 3 days post infection and were still 
clearly evident at 14 days post infection, although some recovery was noted.10 
Together these findings support the hypothesis that CRCoV causes damage to the 
mucociliary clearance mechanisms of the upper airways, which may predispose dogs 
to secondary infections. 
In the first experimental CRCoV infection study to be reported, the pathogenesis of the 
disease resulting from infection with five CRCoV isolates that originated from the UK 
and USA was investigated.10 Following intranasal challenge, all five isolates gave rise 
to clinical signs of respiratory disease (nasal discharge, sneezing, and coughing), 
consistent with clinical signs of naturally occurring disease.4 Viral shedding from the 
oropharynx was readily detected up to 10 days post-infection by RT-PCR and 6 days 
post-infection by virus isolation.10 CRCoV was also detected and re-isolated from a 
wide range of respiratory tissues and respiratory-associated lymphoid tissues 
including trachea, palatine tonsil, nasal cavity, nasal tonsil, bronchial lymph node, 
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cranial and caudal lung lobes, and lung lavage fluids. Consistent with findings from 
kenneled dogs, the trachea and nasal tonsil were the most common sites of infection 
and were also reported to have the highest viral loads. The re-isolation of CRCoV from 
the tissues of experimentally infected dogs with clinical disease fulfilled the final criteria 
for Koch’s postulates and definitively proved a causal relationship between CRCoV 
and respiratory disease in dogs. 
During an investigation of ten kenneled dogs with respiratory disease, CRCoV was 
predominantly detected in respiratory tissues. However, in 2 dogs, CRCoV was also 
detected in the spleen, mesenteric lymph node, and colon.9 The detection of CRCoV 
in gastrointestinal samples suggests that, like some bovine coronavirus strains, 
CRCoV may have the potential to exhibit a dual tropism.11 Further investigation of this 
and the potential clinical consequences is required, although again there is a growing 
body of evidence to suggest SARS-CoV-2 can also infect the gastro-intestinal tract of 
humans and clinical signs of enteric disease have been reported in a significant 
number of patients.1,18  
 
Early anti-viral immune response 
Coronaviruses use multifaceted approaches to counteract host antiviral responses, 
providing an opportunity for viral replication, dissemination within the host and, 
ultimately, the opportunity to infect new hosts. If they can achieve the latter undetected 
by the host immune system (i.e. asymptomatically) then they would be considered 
perfectly host-adapted viruses. Other betacoronaviruses, including SARS-CoV-1, 
have been shown to suppress the activation of antiviral effector genes, and hence 
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reduce the production of pro-inflammatory cytokines, by both passive and active 
inhibition of transcription factor IRF-3.17,6 
Using the air-interface tracheal explant culture system, we examined the messenger 
RNA (mRNA) levels of 3 key pro-inflammatory cytokine genes: interleukin-6, 
interleukin-8, and tumor necrosis factor-α following CRCoV inoculation. mRNA levels 
of all three genes were significantly suppressed, versus medium-only controls, at 24–
48 hours post inoculation.13 During this time, viral load (assessed by RT-qPCR) within 
the tissue remained stable. At 96 hours, there was an increase in viral load and a 
corresponding increase in the mRNA levels of all three cytokines. The implication is 
that the virus is able, by a mechanism not yet fully understood, to suppress the host’s 
early pro-inflammatory immune response, perhaps ‘buying time’ for the infection to 
fully develop.  
This potential ability of betacoronaviruses to suppress early innate immune responses 
for at least 4 days post-infection may offer clues to the widely held view that 
asymptomatic or pre-symptomatic individuals are spreading SARS-CoV-2 as ‘covert 
transmitters’.8 Additionally, although not yet assessed in vivo or if there are strain-
associated differences, the significant rise in IL-6 mRNA levels observed in canine 
tracheal explants at 96 hours (corresponding to the highest levels of virus in the tissue) 
may offer some insights into the most severe expressions of disease (including an 
ARDS-like disease) occurring in some patients.13 IL-6 in particular has been suggested 
as critical for the cytokine release syndrome (CRS, or ‘cytokine storm’) occurring in 
humans with the most severe COVID-19 disease.20  
 
A final word 
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Our knowledge and understanding of SARS-CoV-2 and the resulting disease COVID-
19 is growing by the day and whilst there is a lot still to discover, it would be worth 
taking the time not only to look at historical records of the emergence of 
betacoronaviruses in the human population, but also engage with the veterinary 
community who have been working with coronaviruses in animals for many years. The 
concept of One Health, which had fallen a little out the limelight in recent years, is now 
back full center stage. The veterinary pathologist has a crucial role in bridging the gap 
between human and animal disease using knowledge of infectious diseases in animals 
to inform, collaborate and push forward the One Health concept.  
The exponentially expanding body of peer-reviewed (and non-reviewed) literature on 
SARS-CoV-2 and COVID-19 suggests roles for various wild and domestic animals 
including dogs in the current pandemic, variously as possible sources of the virus, 
intermediate vectors, or simply unwitting fomites. Indeed SARS-CoV-1 is widely 
thought to have infected humans from bats via masked palm civets, whilst dromedary 
camels are considered the hosts for MERS-CoV. Time will tell what species, if any, 
played a role in transmission of SARS-CoV-2 to humans. While some reports have 
definite merit, others are very much computer-based modeling exercises that, whilst 
offering intriguing speculation, present no concrete proof.  
2020 will surely become the year when we as a global society finally move from a 
position of reactivity to a one of proactive horizon-scanning for future threats, 
reasonably safe in the knowledge that it is not IF the next coronavirus will cross the 
species boundary, but WHEN – and we need to be better prepared for that time. 
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Figure legends. 
Figures 1, 2. Human rectal tumor (HRT-18G) cells. Uninfected (Fig. 1) and CRCoV-
infected cells (Fig. 2). Immunofluorescence assay.  
Figures 3, 4. Air-interface ex vivo (‘organotypic’) tracheal culture, dog. Normal (Fig. 
3) and 48 hours after infection with canine respiratory coronavirus (CRCoV) (Fig. 4), 
CRCoV infection results in diffuse loss of cilia and epithelial erosion with sloughing of 
both ciliated and goblet cells. Hematoxylin and eosin (HE) 
Figures 5, 6. CRCoV infection, trachea (Fig. 5) and bronchiole (Fig. 6), dog, 24 hours 
post-infection. Immunolabeling of CRCoV antigen in both ciliated and goblet cells in a 
naturally (Fig. 5) or experimentally infected (Fig. 6) dog. Immunohistochemistry. 
 
 
